-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIN-3248 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KIN-3248 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KIN-3248 in Pancreatic Cancer Drug Details: KIN-3248 is under development for the...
-
Product Insights
Kin Thermal Power Plant
Kin Thermal Power Plant is a thermal project located in Okinawa, Japan. The project is owned and developed by Okinawa Electric Power Co Inc. The project came online in 2002. Empower your strategies with our Kin Thermal Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
NewNet Present Value Model: Kinnate Biopharma Inc’s KIN-002787
Empower your strategies with our Net Present Value Model: Kinnate Biopharma Inc's KIN-002787 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIN-3248 in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KIN-3248 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: KIN-3248 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KIN-3248 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: SynKIR-110 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pyrotinib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pyrotinib in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pyrotinib in Gastric Cancer Drug Details: Pyrotinib maleate (Irene) is an...